Equities research analysts forecast that Evolus, Inc. (NASDAQ:EOLS – Get Rating) will report earnings of ($0.41) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Evolus’ earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.55). Evolus posted earnings of $0.19 per share during the same quarter last year, which suggests a negative year over year growth rate of 315.8%. The company is expected to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Evolus will report full-year earnings of ($1.05) per share for the current fiscal year, with EPS estimates ranging from ($1.13) to ($1.00). For the next financial year, analysts expect that the business will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.78) to ($0.29). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Evolus.
Evolus (NASDAQ:EOLS – Get Rating) last posted its quarterly earnings data on Thursday, March 3rd. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.19. Evolus had a negative return on equity of 60.65% and a negative net margin of 46.96%. The company had revenue of $34.66 million during the quarter, compared to analysts’ expectations of $34.70 million.
In other Evolus news, CMO Crystal Muilenburg sold 6,495 shares of the stock in a transaction that occurred on Tuesday, March 8th. The stock was sold at an average price of $9.73, for a total transaction of $63,196.35. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David Moatazedi sold 6,104 shares of the stock in a transaction that occurred on Monday, March 28th. The stock was sold at an average price of $11.62, for a total value of $70,928.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,571 shares of company stock worth $503,592. 7.60% of the stock is owned by corporate insiders.
Hedge funds have recently modified their holdings of the business. Citigroup Inc. boosted its position in Evolus by 230.9% during the third quarter. Citigroup Inc. now owns 5,090 shares of the company’s stock worth $39,000 after purchasing an additional 3,552 shares in the last quarter. First Quadrant L P CA acquired a new stake in shares of Evolus in the third quarter worth approximately $41,000. Nisa Investment Advisors LLC boosted its stake in Evolus by 945.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,750 shares of the company’s stock worth $43,000 after purchasing an additional 5,200 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in Evolus by 19.5% during the 4th quarter. BNP Paribas Arbitrage SA now owns 6,832 shares of the company’s stock worth $44,000 after purchasing an additional 1,117 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY acquired a new stake in Evolus during the 1st quarter worth $83,000. Institutional investors own 31.34% of the company’s stock.
EOLS traded down $0.10 during trading hours on Friday, reaching $11.28. 172,841 shares of the company’s stock traded hands, compared to its average volume of 371,554. The firm has a 50-day moving average price of $10.27 and a 200 day moving average price of $7.96. Evolus has a 52-week low of $5.06 and a 52-week high of $14.30. The company has a quick ratio of 3.07, a current ratio of 3.10 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $628.18 million, a PE ratio of -13.59 and a beta of 2.19.
Evolus Company Profile (Get Rating)
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
- Get a free copy of the StockNews.com research report on Evolus (EOLS)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.